Hematologic Malignancy
Diffuse Large B-Cell Lymphoma
CI-CAN-00005107DLBCLExplore in graph →
Hematologic355 active trials5 approved drugs19 evidence items
- NCIt
- C8851
- DOID
- 0050745
- Other
- 4 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005107DLBCLExplore in graph →
Clinical trials
1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02752815 | Reduced Chemotherapy in Low Risk DLBCL | unknown | Phase 4 | 290 | Ruijin HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05596097 | Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission | unknown | Phase 2 | 15 | LanZhou UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05575973 |
| Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma |
| unknown |
| Phase 2 |
| 55 |
| Jianfeng ZhouOTHER |
| 1 |
| Oct 12, 2022 |
| clinicaltrials |
| NCT05532761 | Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T Cells(QUALITOP CAR-T) | unknown | — | 30 | Hospices Civils de LyonOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05189782 | Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma | unknown | — | 15 | Ruijin HospitalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT05498636 | SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression | unknown | Phase 1 / Phase 2 | 67 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04226937 | DLBCL Interim Response Evaluation for Customised Therapy(DIRECT) | unknown | — | 150 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT03736616 | Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL | unknown | Phase 2 | 47 | Swedish Medical CenterOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT05444322 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 18 | He HuangOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05381506 | Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma(O-Gemox) | unknown | Phase 2 | 77 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05428670 | The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. | unknown | Phase 2 | 150 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT05414162 | Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy | unknown | — | 60 | University Hospital, BonnOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03971305 | A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL | unknown | — | 300 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05093140 | Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL(CREDIT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Apr 7, 2022 | clinicaltrials |
| NCT04112238 | ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma(CNSctDNA) | unknown | — | 75 | Herlev HospitalOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290337 | ZR-CHOP in DLBCL With Specific Gene Abnormality | unknown | Phase 2 | 62 | Fudan UniversityOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05200312 | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma(ZR2-CHOP) | unknown | Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05269914 | Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL | unknown | N/A | 10 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Mar 8, 2022 | clinicaltrials |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03837873 | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | unknown | Phase 2 | 118 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT03629873 | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | unknown | Phase 2 | 69 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05164770 | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 160 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05097443 | Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 130 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05054426 | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL(NHL-011) | unknown | Phase 3 | 488 | Peking Union Medical College HospitalOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT05039658 | Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) | unknown | Phase 1 | 50 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 9, 2021 | clinicaltrials |
| NCT03720457 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT04610970 | A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） | unknown | Phase 2 | 93 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT04994626 | Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies | unknown | Phase 2 | 20 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 6, 2021 | clinicaltrials |
| NCT04908059 | Leukemic Phase of ALCL(LEUK-ALCL) | unknown | — | 2 | University Hospital, Strasbourg, FranceOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04914143 | the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy | unknown | N/A | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04899570 | Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04842487 | R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study | unknown | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 0 | Apr 13, 2021 | clinicaltrials |
| NCT04825899 | Gene Abnormalities and Prognosis in Diffuse Large B-cell Lymphoma | unknown | — | 100 | Fudan UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04827004 | A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04705129 | Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03800095 | Early Palliative Care for Patients With Haematological Malignancies(CALVI) | unknown | Phase 3 | 140 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT04804865 | Secondary Prognostic Index in RefrActory Lymphoma(SPiRAL) | unknown | — | 180 | WepromOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03000192 | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life | unknown | — | 3,000 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | unknown | Phase 1 / Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04796857 | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL | unknown | Phase 1 / Phase 2 | 30 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT03197259 | Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study(CLLTRegistry) | unknown | — | 1,000 | Fatih Demirkan, MDOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | unknown | Early Phase 1 | 18 | Huazhong University of Science and TechnologyOTHER | 0 | Feb 23, 2021 | clinicaltrials |
| NCT03949062 | Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL | unknown | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT04659434 | Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL | unknown | Phase 2 | 51 | Qian WenbinOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT04025593 | Biomarker Guided Treatment in DLBCL | unknown | Phase 2 | 128 | Ruijin HospitalOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04624893 | A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin | unknown | — | 35 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT04624971 | A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era | unknown | — | 2,000 | Sun Yat-sen UniversityOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT04622579 | Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years(R2DLBCL80) | unknown | Phase 2 | 20 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 10, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Dec 5, 2022source: clinicaltrials